Alzheimer's disease (AD) is characterized by brain plaques containing the beta-amyloid peptide (Aβ). One approach for treating AD is by blocking Aβ aggregation. Activity-dependant neuroprotective protein contains a peptide, NAP that protects neurons in culture against Aβ toxicity. Here, NAP was shown to inhibit Aβ aggregation using: (1) fluorimetry; (2) electron microscopy; (3) high-throughput screening of Aβ deposition onto a synthetic template (synthaloid); and (4) Congo Red staining of neurons. Further assays showed biotin-NAP binding to Aβ. These results suggest that part of the neuroprotective mechanism exerted by NAP is through modulation of toxic protein folding in the extracellular milieu.
- Activity-dependent neuroprotective protein
- Alzheimer's disease
- Aβ aggregation
- Brain-cortical cultures
- Vasoactive intestinal peptide